IP Library Granted Patent US 9,340,577
Granted Patent B2
US 9,340,577 · App. 10/817,970 · Granted May 17, 2016

HLA binding motifs and peptides and their uses

Inventors: Howard M. Grey (La Jolla, CA); Alessandro Sette (La Jolla, CA); John Sidney (La Jolla, CA); Scott Southwood (Santee, CA); Ralph T. Kubo (Carlsbad, CA); Esteban Celis (Rochester, MN); Robert Chesnut (Cardiff-by-the-Sea, CA); W. Martin Kast (La Cañada, CA)
Assignee: Epimmune Inc.
C07K7/06A61K38/10A61K39/02A61K39/12A61K39/145C07K14/70539A61K38/00A61K39/00C07K2319/01C07K2319/33C07K2319/40C12N2710/00088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,340,577
App. No.
10/817,970
Granted
May 17, 2016
Kind
B2
Abstract

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.

Claims (6)

1. A heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ NO: 183) and at least one different peptide, wherein said at least one different peptide is not derived from influenza and is a cytotoxic T cell (CTL)-inducing peptide or a helper T cell (HTL)-inducing peptide.

2. A composition comprising the heteropolymer of claim 1 and a carrier.

3. A composition comprising the heteropolymer of claim 1 and a pharmaceutically acceptable excipient.

4. A composition comprising the heteropolymer of claim 1 .

5. The heteropolymer of claim 1 wherein the isolated immunogenic peptide consists of the oligopeptide NMLSTVLGV (SEQ ID NO: 183).

6. The heteropolymer of claim 1 wherein the at least one different peptide is helper T cell (HTL)-inducing peptide that is PADRE helper peptide having the sequence aKXVAAWILKAAa (SEQ ID NO:14635), wherein a is d-alanine and X is cyclohexylalanine.

Assignments (6)
DECLARATION TO CORRECT AN IMPROPERLY RECORDED ASSIGNMENT UNDER M.P.E.P. 323.01(C) AT REEL 033453, FRAME 0170 Recorded Nov 16, 2015
From: EPIMMUNE INC.
To: EPIMMUNE INC.
Reel/Frame 037184/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →
CHANGE OF NAME Recorded Aug 17, 2012
From: PHARMEXA INC.
To: EPIMMUNE INC.
Reel/Frame 028807/0656 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2006
From: IDM PHARMA, INC.
To: PHARMEXA INC.
Reel/Frame 017115/0860 →
MERGER Recorded Feb 3, 2006
From: EPIMMUNE INC.
To: IDM PHARMA, INC.
Reel/Frame 017115/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2005
From: GREY, HOWARD M.; SETTE, ALESSANDRO; SIDNEY, JOHN; SOUTHWOOD, SCOTT; KUBO, RALPH T.; CELIS, ESTEBAN; CHESNUT, ROBERT; KAST, W. MARTIN
To: EPIMMUNE INC.
Reel/Frame 015718/0382 →
Continuity (106)
Continuation In Part 08821739 · Mar 20, 1997
Continuation In Part 08859107 · Jan 23, 1996
Continuation In Part 08451913 · May 26, 1995
Continuation In Part 08186266 · Jan 25, 1994
Continuation In Part 08159339 · Nov 29, 1993
Continuation In Part 08103396 · Aug 6, 1993
Continuation In Part 08027746 · Mar 5, 1993
Continuation In Part 07926666 · Aug 7, 1992
Continuation In Part 08347610 · Dec 1, 1994
Continuation In Part 08159339
Continuation In Part 08103396
Continuation In Part 08027746
Continuation In Part 07926666
Continuation In Part 10817970
Continuation In Part 09665510 · Sep 19, 2000
Continuation In Part 08347610
Continuation In Part 08159339
Continuation In Part 08103396
Continuation In Part 08027746
Continuation In Part 07926666
Continuation In Part 10817970
Continuation In Part 09017524 · Feb 3, 1998
Continuation In Part 08589107
Continuation In Part 08758409 · Nov 27, 1996
Continuation In Part 08821739
Continuation In Part 08589107
Continuation In Part 08451913
Continuation In Part 08347610
Continuation In Part 08159339
Continuation In Part 08103396
Continuation In Part 08027746
Continuation In Part 07926666
Continuation In Part 08186266
Continuation In Part 08159339
Continuation In Part 08103396
Continuation In Part 08027746
Continuation In Part 07926666
Continuation In Part 10817970
Continuation In Part 09017735 · Feb 3, 1998
Continuation In Part 08205713 · Mar 4, 1994
Continuation In Part 08159184 · Nov 29, 1993
Continuation In Part 08073205 · Jun 4, 1993
Continuation In Part 08027146 · Mar 5, 1993
Continuation In Part 08589108
Continuation In Part 08454033 · May 26, 1995
Continuation In Part 08349177 · Dec 2, 1994
Continuation In Part 08159184
Continuation In Part 08073205
Continuation In Part 08027146
Continuation In Part 08822382 · Mar 20, 1997
Continuation In Part 08753622 · Nov 27, 1996
Continuation In Part 08205713
Continuation In Part 08159184
Continuation In Part 08073205
Continuation In Part 08027146
Continuation In Part 10817970
Continuation In Part 08454033
Continuation In Part 08349177
Continuation In Part 08159184
Continuation In Part 08073205
Continuation In Part 08027146
Continuation In Part 10817970
Continuation In Part 09017743 · Feb 3, 1998
Continuation In Part 08753615 · Nov 27, 1996
Continuation In Part 08590298 · Jan 23, 1996
Continuation In Part 08452843 · May 30, 1995
Continuation In Part 08344824 · Nov 23, 1994
Continuation In Part 08278634 · Jul 21, 1994
Continuation In Part 10817970
Continuation In Part 08452843
Continuation In Part 08344824
Continuation In Part 08278634
Continuation In Part 10817970
Continuation In Part 08344824
Continuation In Part 08278634
Continuation In Part 10817970
Continuation In Part 09226775
Continuation In Part 08815396
Continuation In Part 08485218 · Jun 7, 1995
Continuation In Part 08305871 · Sep 14, 1994
Continuation In Part 08121101 · Sep 14, 1993
Continuation In Part 10817970
Continuation In Part 10030014
Continuation In Part 10817970
Continuation In Part 10121415 · Apr 11, 2002
Continuation In Part 09189702 · Nov 10, 1998
Continuation In Part 09098584 · Jun 17, 1998
Continuation In Part 10817970
Continuation In Part PCTUS0331308 · Oct 3, 2003
Continuation In Part 10817970
Continuation In Part 09260714 · Mar 1, 1999
Continuation In Part 10470364
Continuation In Part 09935476 · Aug 22, 2001
Continuation In Part 09346105 · Jun 30, 1999
Continuation In Part 10817970
Continuation In Part 10469201
Provisional Application 60013833 · Mar 21, 1996
Provisional Application 60013980 · Mar 21, 1996
Provisional Application 60013113 · Mar 11, 1996
Provisional Application 60141422 · Jun 29, 1999
Provisional Application 60416207 · Oct 3, 2002
Provisional Application 60417269 · Oct 8, 2002
Provisional Application 60264969 · Jan 29, 2001
Provisional Application 60285264 · Apr 20, 2001
Provisional Application 60242350 · Oct 19, 2000
Related Publication 20070055049A1 · Mar 8, 2007